Kornimate/medical-research-clean huggingface dataset:
ticagrelor and asa vs. asa only after isolated coronary artery bypass grafting in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the study is a randomised registry-based clinical trial (rrct) to assess whether dual antiplatelet therapy with ticagrelor and asa compared to asa alone improves outcome after isolated cabg in patients with acute coronary syndrome.

the trial is a 1:1 randomized, interventional, multi-national, multi-center, safety/efficacy, parallel assignment, open-label treatment study and will use the rrct methodology. a rrct study utilizes existing health care registry platforms to conduct a pragmatic prospective randomized trial. after the cabg, eligible patients that have consented to the study, will be randomized to either treatment arms. in the intervention arm, patients will be treated with ticagrelor 90 mg twice daily and asa 75-100 mg daily for 12 months and patients in the control arm will get asa only (75-160 mg daily according to local guidelines) during the same time period. the patients will be followed by telephone interviews at 30 days and 365 days after inclusion. after the treatment period patients will be followed during an observation period by collection of outcome data from registries or medical records, 24, 36, 60 and 120 months after inclusion of the patient. no other data but the registry data or data from medical records will be collected.

Eligibility criteria:
inclusion criteria: 1. written informed consent 2. age ≥18 years 3. has undergone first time isolated cabg due to an episode of acute coronary syndrome (stemi, nstemi, unstable angina) within 6 weeks before surgery exclusion criteria: 1. previously enrolled in this study (i.e. patient now at repeat encounter) 2. concomitant surgical procedure other than cabg 3. anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), fxa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux) 4. discharge from the operating hospital to an icu at another hospital 5. pregnancy or lactation 6. known intolerance or contraindication to ticagrelor or asa 7. any disorder that may interfere with drug absorption 8. any condition other than coronary artery disease with a life expectancy \<12 months 9. known chronic liver disease, renal disease requiring dialysis or bleeding disorder 10. atrioventricular block ii and iii in patients without pacemaker 11. any other indication for dual antiplatelet therapy, i.e. recent stent implantation 12. debilitating stroke within 90 days before inclusion 13. previous intracranial bleeding 14. treatment with immunosuppressants (e.g. cyclosporine and tacrolimus) 15. treatment with strong cyp3a4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir) 16. any condition that in the opinion of the investigator may interfere with adherence to trial protocol 17. participation in any other clinical trial evaluating investigational products at the time for enrollment in this study

Keywords: coronary bypass grafting antiplatelet treatment
clinical pathway for alzheimer's disease in china (cpad)

Conditions: Mild Cognitive Impairment; Alzheimer's Disease; Dementia

Summary: there are guidelines on the management of ad in china, the evidence adopted in the guidelines are mostly from the trials conducted in other countries due to very limited chinese data available for local systematic review. therefore, more local evidence on dementia care is needed for the development of an evidence-based guideline appropriate for people living in china. meanwhile, the inadequate implementation of the current ad guideline, which results in the low diagnostic rate and high diagnostic leakage, may bring about extra barriers for ad patients to access dementia care service in different areas nationwide. however, there is no data on the clinical pathway about how physicians follow the dementia guideline in the routine practice. therefore, research is needed to learn clinical diagnostic process and treatment patterns of physicians to people with ad in routine practice and help address the low accurate rate of ad clinical diagnosis and low anti-dementia drug prescription in the real world and support guideline development.

outpatients who are visiting memory clinics and who are judged by physicians with clinically significant cognitive impairment will be invited to join the study during the study recruiting period (with informed consent signed). * patients enrolled into the study will be evaluated and diagnosed by participating physicians and may or may not be prescribed with therapy (pharmaceutical and/or non-pharmaceutical) based on physicians' medical judgment. * for patients with routine clinical follow-up visits, their medical charts will be reviewed for documentation. the procedures of making diagnosis and developing treatment scheme will be retrieved and documented in clinical report form (crf). additional procedures ordered by the participating physician at current visits will also be documented in crf. all participants will be followed twice after baseline visit to re-evaluate and confirm the initial diagnosis (where applicable), and to record compliance to treatment scheme, including the process of medication titration. this study does not recommend nor restrict any specific treatments.

Eligibility criteria:
inclusion criteria: * male and female outpatients with clinically significant cognitive impairment per independent judgment of participating physicians; * aged 45 year old and above; * willing to receive 2 follow-up visits; * having at least one informant or caregiver accompanying during each visit; * willing to join the study and sign the informed consent prior to the study. exclusion criteria: * cognitive impairment is likely or identified as secondary to other disease condition(s) than ad (including but not limited to stroke, parkinson's disease, brain trauma, central nervous system infection, etc.) * unwilling to participate in the study; * participating other studies during the registry study period.
vitamin d and prebiotics for intestinal health in cystic fibrosis

Conditions: Cystic Fibrosis; Dysbiosis

Summary: the study will assess if administration of high-dose vitamin d and a commonly used prebiotic (inulin) is effective to reduce gastrointestinal dysbiosis and to improve critical intestinal functions in cystic fibrosis with the additive or synergistic effects of the combination of vitamin d + inulin.

cystic fibrosis (cf) is the most common life-shortening genetic condition among caucasians in the united states. individuals with cf have an altered gastrointestinal (gi) microbiota, which may be a result of chronic systemic inflammation and infection, frequent use of antibiotics, and/or medically prescribed and habitual high-fat/high-calorie diets. the study will assess if administration of high-dose vitamin d and a commonly used prebiotic (inulin) is effective to reduce gastrointestinal dysbiosis and to improve critical intestinal functions in cystic fibrosis.

Eligibility criteria:
inclusion criteria: 1. male and female patients (age \> 18 years) with confirmed cf by genetic mutation and/or sweat chloride testing, 2. not currently on oral or systemic antibiotics for pulmonary exacerbation, 3. vitamin d deficient/insufficient (25(oh)d, 6 - 30 ng/ml) with most recent 25(oh)d in the past 12 months, 4. use of cftr modulator therapy is allowed exclusion criteria: 1. severe vitamin d deficiency 25(oh)d ≤ 5 ng/ml or hypocalcemia or hypercalcemia, 2. active gi disease, abdominal pain and/or diarrhea, 3. chronic kidney disease worse than stage 3 (egfr \< ml/min per 1.73 m2), 4. any vitamin d supplement use \>2,000 iu or vitamin d analogue (patients who are taking more than 2,000 iu of vitamin d must agree to stop the vitamin d for 6 weeks and take less than 2,000 iu of vitamin d during the study), 5. use of immunosuppressants or history of organ transplantation, 6. current use of probiotics or prebiotics

Keywords: cystic fibrosis gastrointestinal dysbiosis vitamin d prebiotic inulin gut microbiome intestinal inflammation intestinal absorption
clinical trial to evaluate the safety and efficacy of breast implant

Conditions: Breast Cancer

Summary: the aim of this study is to evaluate the safety and efficacy of cohesive silicone gel-filled breast implant (cosbi) produced by hansbiomed co.,ltd. in breast reconstruction or augmentation


Eligibility criteria:
inclusion criteria: * over 22 years of age * subjects who want breast augmentation reconstruction following breast cancer, congenital or accidental unbalanced breast size * negative pregnancy test in fertile women * subjects who voluntarily decided the participation of the study and signed the informed consent * subjects who can understand and comply with the instructions and participate during the entire period of the trial exclusion criteria: * previous breast reconstruction or augmentation history * self -immune disease * uncontrolled active infectious disease * unable to insert beast implant due to radiotherapy * patients who have recurrent breast cancer or do not treat effectively their cancer * keloid * abnormal blood test or ecg result for general anesthesia * patients who cannot mri scan due to having metallic substance in the body or claustrophobia * aesthetic addiction, drug abuse, alcohol abuse * patients who are not eligible for this study at the medical discretion of the principal investigator or sub-investigator

Keywords: breast cancer reconstruction augmentation cohesive silicone gel breast implant rupture capsular contracture
hpvpro study: comparison of hpv detection in clinician-collected cervical swabs and self-sampled cervicovaginal swabs

Conditions: Cervical Cancer; Cervical Dysplasia; Human Papillomavirus Infection

Summary: comparison of the detection of human papillomavirus dna in paired physician-obtained cervical swabs and self-sampled cervicovaginal swabs and evaluation of hpv prevalence in czech women screening population.

the cervical screening program in the czech republic is based on cytology with hpv triage. nevertheless, cytology-based cervical screening may switch to hpv-based cervical screening in future. the implementation of primary hpv screening and insuficiency cervical screening attendance are a major challenge. the offering of self-sampling to the cervical screening non-attenders could increase women's participation as was shown in several european countries. the objective of the hpvpro study was to find out the hpv prevalence in the screening population of czech women since there are no data for the czech republic. the second objective was to compare hpv dna detection rate in paired self-sampled cervicovaginal swabs and physician-obtained cervical swabs and to determine acceptability of self-sampling hpv dna test by czech women. this information is important for optimisation of cervical cancer screening program in the czech republic.

Eligibility criteria:
inclusion criteria: * women with age 30-64 years. * women attending cervical cancer screening program in czech republic. * women with completed informed consent. exclusion criteria: * pregnant women. * women with no sexual intercourse experience. * women after cervical conization or hysterectomy. * women with cin or cervical carcinoma in anamnesis. * women at risk of increased bleeding.

Keywords: human papillomavirus hpv self-sampling cervical swab cervicovaginal swab cervical cancer screening
standardized clinical assessment of patients with leptomeningeal metastasis

Conditions: Leptomeningeal Metastasis; Leptomeningeal Disease; Leptomeningeal Neoplasms; Leptomeningeal Cancer

Summary: the goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.


Eligibility criteria:
inclusion criteria: * adult patients (18 years or more), female or male * histologically confirmed diagnosis of extra-cns primary solid cancer * diagnosis of leptomeningeal metastases confirmed or probable per eano esmo criteria * performance status compatible with enrolment into clinical trials * ability to consent * signed informed consent form from patient * participation in a parallel clinical trial is allowed in this non-interventional study exclusion criteria: * inability to give informed consent * inability to adhere to recommended follow-up according to the treating physician vulnerable participants will not be included.
administration of pre-operative gabapentin to patients undergoing laparoscopy

Conditions: Postoperative Pain

Summary: the purpose of this study is to prospectively determine the influence of immediate pre-operative gabapentin administration on acute postoperative pain. the investigators hypothesize that immediate post-operative pain will be improved with pre-operative administration of gabapentin.

the purpose of this study is to prospectively determine the influence of immediate pre-operative gabapentin administration on acute postoperative pain. we hypothesize that immediate post-operative pain will be improved with pre-operative administration of gabapentin. we plan to conduct a prospective randomized trial to assess the effect of a single immediate pre-operative dose of gabapentin 300mg on immediate post-operative pain in patients undergoing laparoscopy for gynecologic indications. this concept has been studied in patients undergoing abdominal hysterectomy. we aim to study the effect on patients undergoing laparoscopy.

Eligibility criteria:
inclusion criteria: 1. the patient must be female and planning to have a laparoscopic or robotic assisted procedure for benign gynecologic indications. 2. patients must be treated in the department of obstetrics and gynecology in the division of minimally invasive gynecologic surgery. 3. the patient must be in the age range of 18-80 years, in general good health and able to comply with study procedures. exclusion criteria: 1. male patients will be excluded from this study. 2. patients under 18 years old will be excluded from this study. 3. pregnant patients. all patients will have a routine pre-operative urine hcg to exclude pregnancy. 4. patients having abdominal, vaginal or hysteroscopic procedures 5. allergy to gabapentin 6. chronic use of gabapentin (greater than 6 months)

Keywords: laparoscopy postoperative pain gynecology gabapentin
evaluating the safety and efficacy of telemedicine neurology assessments on a mobile stroke unit

Conditions: Ischemic Stroke; Intracerebral Hemorrhage

Summary: the goal of this clinical trial is to compare a telemedicine neurologist staffing model to a traditional on-board model in patients being assessed for suspected acute stroke on a mobile stroke unit.

this study is a prospective randomized mobile stroke unit trial comparing two staffing models: 1) a neurologist reviewing the patient via telemedicine (intervention) versus 2) an onboard neurologist assessing the patient in-person (comparator). daily periods of remote (telemedicine) or in person (onboard) neurologist assessments will be randomly determined using an adaptive design.

Eligibility criteria:
inclusion criteria: 1. adults \>=18 years of age 2. presenting within 24 hours of symptom onset or last known well. 3. patients assessed by msu without cancellation (either by the local ambulance team or by msu) prior to attending the patient. exclusion criteria: 1. attendance of the melbourne msu is deemed unnecessary by either the local paramedic team or the msu team based on provided information prior to arrival on scene. 2. the patient presents significant medical or logistical challenges which greatly delay standard treatment. 3. any other medical contraindication at the discretion of the investigator.

Keywords: mobile stroke unit stroke
eln 2022 in menafc ( middle eastern or north coast of africa ) patients with newly aml

Conditions: Leukemia, Myeloid

Summary: "in daily clinical practice, 2022 eln guidelines were used to predict response to conventional treatment and to guide the need for allogenic stem cell transplantation. but, the team has to underline that eln guidelines are mainly reflective of relatively young caucasian patients. few studies have compared 2017 and 2022 eln in ethnicity cohorts to evaluate the potential prognostic value of this new criteria in these types of population. for example, with the 2022 eln guidelines, the disease-free surviva) and the overall survival of african american \< 60 y.o were not statistically different between intermediate and adverse groups (p=0.30, p=0,46). there were not a significant difference between favorable and intermediate groups in dfs (p=0.42, p=0.42) respectively in african american and hispanic patients or in os (p=0.67) in hispanic patients. is the 2022 eln applicable to all ethnic subgroups? to date, no studies have examined and validated its applicability in middle eastern or north coast of africa (menafc) patients."


Eligibility criteria:
inclusion criteria: * newly diagnosed aml * at least 18 yo * menafc (middle east ern of north coast of africa) patients with hla hla \> 50% * ecog performance status of 0,1,2,3" exclusion criteria: * acute promyelocytic leukemia * patients alive at the start of the study who did not receive study information or who objected to the collection of data"
a comparison of the effect of target-controlled infusion anesthesia and inhalation anesthesia

Conditions: Pediatric Patients; Cardiology

Summary: a total of 70 patients who underwent angiographic examination, asd closure, vsd closure, pda closure and aortic balloon dilatation were included in this study.

a total of 70 patients who underwent angiographic examination, asd closure, vsd closure, pda closure and aortic balloon dilatation were included in this study. patients underwent standard electrocardiography (ecg) monitoring with heart rate (hr), noninvasive blood pressure (nikb), peripheral oxygen saturation (spo2) and bispectral index (bis). baseline nikb, spo2 and hr were recorded before the procedure, intraoperatively and in the postoperative recovery unit. in the postoperative recovery unit, the patient's recovery time was also evaluated and recorded with the modified aldrete recovery score.

Eligibility criteria:
inclusion criteria: 1. children weighing over 10 kg and between the ages of 3-18 who will undergo angiography 2. patients who are not allergic to the drugs used exclusion criteria: 1. asa ⅳ patients 2. patients with diabetes mellitus 3. patients with severe lung disease 4. patients with psychiatric disorders 5. patients with opioid addiction -

Keywords: sevoflurane, propofol target controlled infusion,
a study of as1411 combined with cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: this is an open label randomized controlled phase ii study of as1411 combined with cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.


Eligibility criteria:
inclusion criteria: * diagnosis of aml as defined by the world health organization (who) classification (vardiman 2009) * primary refractory aml (defined as a failure to achieve a cr or cri after therapy with curative intent) or aml in first relapse * ecog performance status 0, 1 or 2 * age \> 18 and \< 70 years * for patients presenting with primary refractory aml, \> 20% blasts on baseline bone marrow assessment * for patients presenting with relapsed aml, \> 5% blasts on baseline bone marrow assessment exclusion criteria: * an initial diagnosis of acute promyelocytic leukemia (as defined by french-american-british criteria (bennett 1976)) * secondary aml, defined as aml evolving from antecedent hematological disorder or prior exposure to leukemogenic therapy or agent * clinically active cns leukemia * previously received a total cumulative dose of cytarabine \> 6g/m2 in the last 6 months * previously received \> 1 induction regimen (defined as 1 or 2 cycles of a drug or a drug combination administered as remission induction therapy)

Keywords: as1411 aml relapsed refractory aptamer nucleolin
gastric ultrasound in term pregnants

Conditions: Pregnancy; Diabetes

Summary: in this study, the investigators aimed to evaluate the gastric antrum with ultrasound and compare gastric volumes in diabetic and non-diabetic pregnant women in the standard fasting state before surgery. the primary aim was qualitative assessment, while secondary objectives included quantitative assessment, comparing gastric volume, aspiration risk, and the effect of preoperative anxiety on stomach contents.

food residues in the stomach of patients scheduled for surgery are a major risk factor for pulmonary aspiration, leading to significant morbidity and mortality. this risk is particularly critical in pregnant women who may require surgery without proper fasting. national guidelines recommend fasting for 6 hours for solid foods, 4 hours for breast milk, and 2 hours for clear liquids. these guidelines apply equally to adults and children. pregnant patients scheduled for elective surgery follow the same fasting rules as non-pregnant patients. gastroparesis, defined as delayed gastric emptying without mechanical obstruction, affects 30-50% of diabetic (dm) patients. ultrasound measurement of the gastric antral area can help identify whether the stomach is full in symptomatic patients. gastric ultrasound is a valuable tool for assessing aspiration risk in pregnant women, especially during emergency surgeries, and has shown promise in fasting non-pregnant patients scheduled for elective surgery. in this study, the investigators aimed to evaluate the gastric antrum using ultrasound and compare gastric volumes in diabetic and non-diabetic pregnant women in a standard fasting state before surgery. the primary goal was qualitative assessment, with secondary objectives including quantitative assessment, comparing gastric volume, aspiration risk, and the effect of preoperative anxiety on stomach contents.

Eligibility criteria:
inclusion criteria: 1. patients with good mental status 2. pregnant patients aged ≥18 years 3. patients in asa ii-iii group 4. patients complying with preoperative fasting instructions (at least 6 hours for solids, at least 2 hours for clear liquids) 5. term pregnant women (gestational age ≥ 36 weeks) 6. 50-120kg weight 7. 150cm height or taller 8. written informed consent exclusion criteria: 1. taking any medication known to accelerate or delay gastric emptying, including (but not limited to) opioid-containing medications and antacids. 2. gastroesophageal reflux, abnormal anatomy of the upper gastrointestinal tract, previous surgical procedures for the esophagus or upper abdomen, etc. any stomach complaints 3. pregnant women with term labor or obstetric emergency 4. twin pregnancy -

Keywords: gastric ultrasound term pregnant preoperative fasting